New Study Addresses FDA's Concerns, Demonstrates CBD's Safety Profile

New Study Addresses FDA's Concerns, Demonstrates CBD's Safety Profile
Cannabtimes

<![CDATA[A recent study released by Validcare directly addresses the U.S. Food and Drug Administration’s (FDA) safety concerns regarding CBD’s effects on the liver, testosterone levels and drowsiness.The FDA’s safety concerns state that CBD in self-dosing individuals could cause liver injury, male reproductive toxicity, or damage males’ fertility, and increase the risk of sedation and drowsiness when mixed with alcohol or other drugs that slow brain activity.The study, completed March 22, 2022, observed the effects of daily consumption of CBD on the liver, testosterone and daytime drowsiness. According to the abstract, the study included 1,061 adults ranging from 18-75 years old from across the U.S.The adults were divided into two cohorts. Both cohorts followed the same methods and took CBD orally for a minimum of 30 days. The adults “were recruited from 17 individual CBD product companies in this decentralized, observational study and sent their standard CBD regimen from the company of their choice,” the abstract states.The first cohort of the study (cohort 1)—which was peer-reviewed and published in Cannabis and Cannabinoid Medicine last year—involved 839 individuals who took CBD produced by 12 companies. Cohort 2 added 222 individuals who took CBD from an additional five companies. Cohort 1 used liver function as the primary endpoint. In addition to liver function, cohort 2 focused on testosterone levels and daytime drowsiness. The combined results of each cohort found that CBD “is not associated with an increased prevalence of LFT [liver function tests] elevation, testosterone deficiency, nor daytime drowsiness,” according to the study. The results suggest that CBD may help reduce testosterone deficiency in men, “which may be related to CBD reducing the prevalence of Type 2 diabetes in older individuals,” the abstract states.  Daytime drowsiness was measured using the Stanford Sleepiness Scale (SSS), which measures sleepiness on a seven-point scale. The study found that the…

Excerpt only …
READ MORE BELOW
Source : New Study Addresses FDA's Concerns, Demonstrates CBD's Safety Profile

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.